Renalytix plc (RNLX) Financial Statements (2024 and earlier)
Company Profile
| Business Address |
FINSGATE LONDON, EC1V 9EE |
| State of Incorp. | DE |
| Fiscal Year End | June 30 |
| Industry (SIC) | 8071 - Medical Laboratories (benchmarking) |
| More info | Complete Financial Analysis Financial Benchmarking |
Balance Sheet (Statement of Financial Position) ($ in thousands)
| 3/31/2024 MRQ | 6/30/2023 | |||
|---|---|---|---|---|
| ASSETS | ||||
| Current Assets | ||||
| Cash, cash equivalents, and short-term investments | 24,682 | |||
| Cash and cash equivalents | 24,682 | |||
| Receivables | 776 | |||
| Other undisclosed current assets | 1,424 | |||
| Total current assets: | 26,882 | |||
| Noncurrent Assets | ||||
| Operating lease, right-of-use asset | 159 | |||
| Property, plant and equipment | 1,027 | |||
| Intangible assets, net (including goodwill) | 1,050 | |||
| Intangible assets, net (excluding goodwill) | 1,050 | |||
| Deferred costs | 1,100 | |||
| Other undisclosed noncurrent assets | 411 | |||
| Total noncurrent assets: | 3,747 | |||
| TOTAL ASSETS: | 30,629 | |||
| LIABILITIES AND EQUITY | ||||
| Liabilities | ||||
| Current Liabilities | ||||
| Accounts payable and accrued liabilities | 6,644 | |||
| Accrued liabilities | 6,644 | |||
| Debt | 4,463 | |||
| Other undisclosed current liabilities | 5,029 | |||
| Total current liabilities: | 16,136 | |||
| Noncurrent Liabilities | ||||
| Long-term debt and lease obligation | 7,485 | |||
| Long-term debt, excluding current maturities | 7,485 | |||
| Liabilities, other than long-term debt | 41 | |||
| Operating lease, liability | 41 | |||
| Total noncurrent liabilities: | 7,526 | |||
| Total liabilities: | 23,662 | |||
| Equity | ||||
| Equity, attributable to parent | 6,967 | |||
| Common stock | 286 | |||
| Additional paid in capital | 186,456 | |||
| Accumulated other comprehensive loss | (1,450) | |||
| Accumulated deficit | (178,325) | |||
| Total equity: | 6,967 | |||
| TOTAL LIABILITIES AND EQUITY: | 30,629 | |||
Income Statement (P&L) ($ in thousands)
| 3/31/2024 TTM | 6/30/2023 | ||
|---|---|---|---|
| Revenues | 3,403 | ||
| Cost of revenue | (2,683) | ||
| Gross profit: | 720 | ||
| Operating expenses | (42,941) | ||
| Operating loss: | (42,221) | ||
| Nonoperating income | 1,014 | ||
| Gain, foreign currency transaction, before tax | 358 | ||
| Other nonoperating income | 656 | ||
| Loss from continuing operations before equity method investments, income taxes: | (41,207) | ||
| Loss from equity method investments | (9) | ||
| Other undisclosed loss from continuing operations before income taxes | (4,389) | ||
| Loss from continuing operations before income taxes: | (45,605) | ||
| Income tax expense | (2) | ||
| Net loss available to common stockholders, diluted: | (45,607) | ||
Comprehensive Income ($ in thousands)
| 3/31/2024 TTM | 6/30/2023 | ||
|---|---|---|---|
| Net loss: | (45,607) | ||
| Comprehensive loss: | (45,607) | ||
| Comprehensive loss, net of tax, attributable to noncontrolling interest | (46,142) | ||
| Comprehensive loss, net of tax, attributable to parent: | (91,749) | ||
Statements Sources
The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.